File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tumor resensitization to erlotinib following brief substitution of cetuximab

TitleTumor resensitization to erlotinib following brief substitution of cetuximab
Authors
KeywordsEpidermal growth factor receptor
Receptor antibodies
Sequential drug scheduling
Targeted anticancer drugs
Tyrosine kinase inhibitors
Issue Date2008
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 2008, v. 62 n. 6, p. 1111-1112 How to Cite?
AbstractTargeted inhibition of epidermal growth factor receptors (EGFR) is becoming a standard anticancer treatment in defined clinical scenarios. EGFR inhibition may be achieved either by small-molecule orally bioavailable tyrosine kinase inhibitors, such as gefitinib or erlotinib, or else by large-molecule receptor antibodies, such as cetuximab or panitumumab. Here, we describe a case of pancreatic cancer in which the small-molecule EGFR antagonist erlotinib was used before and after the EGFR antibody cetuximab, with unexpected potentiation of both toxic and therapeutic sequelae. © 2008 Springer-Verlag.
Persistent Identifierhttp://hdl.handle.net/10722/77974
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorEpstein, RJen_HK
dc.contributor.authorLeung, TWen_HK
dc.date.accessioned2010-09-06T07:37:47Z-
dc.date.available2010-09-06T07:37:47Z-
dc.date.issued2008en_HK
dc.identifier.citationCancer Chemotherapy And Pharmacology, 2008, v. 62 n. 6, p. 1111-1112en_HK
dc.identifier.issn0344-5704en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77974-
dc.description.abstractTargeted inhibition of epidermal growth factor receptors (EGFR) is becoming a standard anticancer treatment in defined clinical scenarios. EGFR inhibition may be achieved either by small-molecule orally bioavailable tyrosine kinase inhibitors, such as gefitinib or erlotinib, or else by large-molecule receptor antibodies, such as cetuximab or panitumumab. Here, we describe a case of pancreatic cancer in which the small-molecule EGFR antagonist erlotinib was used before and after the EGFR antibody cetuximab, with unexpected potentiation of both toxic and therapeutic sequelae. © 2008 Springer-Verlag.en_HK
dc.languageengen_HK
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_HK
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_HK
dc.subjectEpidermal growth factor receptoren_HK
dc.subjectReceptor antibodiesen_HK
dc.subjectSequential drug schedulingen_HK
dc.subjectTargeted anticancer drugsen_HK
dc.subjectTyrosine kinase inhibitorsen_HK
dc.titleTumor resensitization to erlotinib following brief substitution of cetuximaben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0344-5704&volume=&spage=&epage=&date=2008&atitle=Tumor+resensitization+to+erlotinib+following+brief+substitution+of+cetuximab.en_HK
dc.identifier.emailEpstein, RJ: repstein@hku.hken_HK
dc.identifier.authorityEpstein, RJ=rp00501en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00280-008-0698-6en_HK
dc.identifier.pmid18283460-
dc.identifier.scopuseid_2-s2.0-51849132830en_HK
dc.identifier.hkuros150569en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-51849132830&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume62en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1111en_HK
dc.identifier.epage1112en_HK
dc.identifier.isiWOS:000259189100020-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridEpstein, RJ=34975074500en_HK
dc.identifier.scopusauthoridLeung, TW=16151388900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats